Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury

Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology

Jan Groen, Jürgen Pannek, David Castro‐Díaz et al. · European Urology · 2015 · 578 citations

Medicine, Surgery, Urology +12

EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction

M. Stöhrer, Bertil Blok, David Castro‐Díaz et al. · European Urology · 2009 · 565 citations

Medicine, Surgery, Urology +12

Safety and efficacy of mirabegron as ‘add‐on’ therapy in patients with overactive bladder treated with solifenacin: a post‐marketing, open‐label study in Japan ( <scp>MILAI</scp> study)

Osamu Yamaguchi, Hidehiro Κakizaki, Yukio Homma et al. · British Journal of Urology · 2015 · 101 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Mirabegron 50 mg once‐daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year

Christopher R. Chapple, Steven A. Kaplan, David Mitcheson et al. · International Journal of Urology · 2014 · 46 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Urodynamic Evaluation of the Efficacy of Mirabegron on Storage and Voiding Functions in Women With Overactive Bladder

Yoshihisa Matsukawa, Shun Takai, Yasuhito Funahashi et al. · Urology · 2015 · 33 citations

Medicine, Pharmacotherapy, Urology +16